Street Calls of the Week
LONDON - Ananda Pharma plc (AQSE:ANA, OTCQB: ANANF) announced today it will hold its Annual General Meeting (AGM) on August 26, 2025, at 2:00 pm BST at the offices of Arch Law in London.
The UK-based biopharmaceutical company, which focuses on developing cannabidiol medicines for chronic conditions, has sent the notice of meeting to shareholders, according to a press release statement.
Prior to the AGM, Chief Executive Officer Melissa Sturgess will deliver a corporate update presentation with a Q&A session via the company’s InvestorHub on August 12 at 12:00 pm. The presentation will be open to existing and potential shareholders, with questions accepted until August 11 or during the live event.
Ananda Pharma is currently developing regulatory approved cannabidiol medicines targeting epilepsy, endometriosis, and chemotherapy pain. The company’s epilepsy trials are funded by NHS England and NIHR, while its endometriosis research receives funding from NHS Scotland, and its chemotherapy pain studies are supported by NIHR.
The company noted that full details of the resolutions proposed to shareholders are available within the Notice of Meeting on the company’s investor website.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.